2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl Bromide | 132451-32-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl Bromide
• 英文别名: 4-bromoethyl-5-methyl-2-phenyl-1,3-oxazole；4-(2bromoethyl)-5-methyl-2-phenyloxazole；2-(5-methyl-2-phenyloxazol-4-yl)ethylbromide；5-methyl-2-phenyl-4-(2-bromoethyl)-oxazole；4-(2-bromoethyl)-5-methyl-2-phenyloxazole；4-(2-bromo-ethyl)-5-methyl-2-phenyl-oxazole；4-(2-bromoethyl)-5-methyl-2-phenyl-1,3-oxazole
• CAS: 132451-32-2
• 化学式: C₁₂H₁₂BrNO
• 分子量: 266.137
• InChiKey: CZZOZGQJNRENHG-UHFFFAOYSA-N

物化性质

• 沸点：
  357.6±34.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl Bromide 在 potassium tert-butylate 、 乙酸酐 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.58h， 生成 ethyl 2-cyano-2-[2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-1,1-dioxo-1,2-benzothiazol-3-ylidene]acetate
  参考文献：
  名称：

  Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents

  摘要：

  Compounds from two novel series of spirosuccinimides were prepared. Analogs of series 2 possessed a spiro-fused isoindolone moiety while those of series 3 contained a spiro-fused benzisothiazole S,S-dioxide group. These compounds were evaluated as aldose reductase inhibitors (ARI) in vitro by their ability to inhibit glyceraldehyde reduction using a partially purified bovine lens aldose reductase preparation and in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. Many members from the isoindolone series 2, particularly those containing an isoindolone N-methyl moiety, showed good in vitro and in vivo potency. The most potent member, the 6-chloro analog 32, was resolved, and aldose reductase activity was found to reside almost exclusively in the (+)-enantiomer. Compound 32 was approximately equipotent in the sciatic nerve of the galactose-fed rat to other cyclic imide ARI's of similar in vitro activity, namely sorbinil and ADN-138 and also to tolrestat, an acetic acid-based ARI (ED50's 4-8 mg/kg). Compounds from both series, 2 and 3, were also found to lower plasma glucose levels of genetically obese db/db and ob/ob mice with potency similar to that of ciglitazone. However, members from these series failed to lower insulin levels of the ob/ob mouse at the doses tested.

  DOI：

  10.1021/jm00102a016
• 作为产物：
  描述：

  methyl 3-benzamido-4-oxovalerate 在 lithium aluminium tetrahydride 、 四溴化碳 、 三苯基膦 、 三氯氧磷 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 8.17h， 生成 2-(5-Methyl-2-phenyl-4-oxazolyl)ethyl Bromide
  参考文献：
  名称：

  新型噻唑烷-2,4-二酮类药物作为有效的高血糖药。

  摘要：

  通过用各种官能团即酮，醇或烯烃部分取代恩格列酮的醚官能团，获得了一系列新的噻唑烷-2,4-二酮。这些化合物可降低遗传性肥胖和胰岛素抵抗的ob / ob小鼠的血糖水平。在链的末端附加基于恶唑基的基团提供了高效的化合物。

  DOI：

  10.1021/jm00088a022

文献信息

• Antidiabetic agents
  申请人：——

  公开号：US20030171377A1

  公开（公告）日：2003-09-11

  The present invention provides compounds of Formula (I): 1 wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

  本发明提供了式(I)的化合物： 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值，以及药用可接受的盐，这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物，制备式I化合物的方法，以及用于制备式I化合物的中间体。
• Indolyl derivatives as liver-X-receptor (LXR) modulators
  申请人：Dehmlow Henrietta

  公开号：US20050245515A1

  公开（公告）日：2005-11-03

  The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.

  这项发明涉及式(I)的化合物： 以及其药学上可接受的盐和药学上可接受的酯，其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，A，m，n和p的定义如权利要求书中所述。 这些化合物可用作治疗糖尿病等疾病的药物组合物。
• Ether and amide compounds and preparation of thereof as antidiadetics.
  申请人：——

  公开号：US20010008898A1

  公开（公告）日：2001-07-19

  Ether and amide derivatives are disclosed, which are represented by the following formula (I) and its pharmaceutical acceptable salt, and which are useful for the treatment of diabetes. 1 (with the provisos that (i) when A is —O—, then n is 2 or 3 (ii) when A is 2 then n is 1 or 2. R 3 is OH—, CH 3 SO 2 NH—, CF 3 SO 2 NH—, CH 3 SO 2 NHCH 2 —, CF 3 SO 2 NHCH 2 —, HOOC—, CH 3 OOC—, 3 HOOC—CH 2 SO 2 NH—, CF 3 —CH 2 SO 2 NH—, 4 R 8 —NHSO 2 —, R 8 —NHSO 2 —CH 2 —, HOOC—CH 2 —O—, HSO 3 N═CH—, or R 9 —SO 2 NHCO—; R 4 is H, OH, O-alkyl or O—CH 2 OCH 3 ; R 5 is H, halogen atom, —CH 2 COOH or OH; R 6 and R 7 are hydrogen, t-butyl or pyrolidyl; R 8 is hydrogen or lower alkyl; R 9 is alkyl or thienyl; R 10 is lower alkyl) or a pharmaceutically acceptable salt.

  乙醚和酰胺衍生物被披露，其由以下式(I)及其药用可接受盐所代表，并且对于糖尿病的治疗是有用的。 1 （在以下情况下，附加条件为：(i) 当A为—O—时，n为2或3 (ii) 当A为 2 时，n为1或2。R 3 为OH—，CH 3 SO 2 NH—，CF 3 SO 2 NH—，CH 3 SO 2 NHCH 2 —，CF 3 SO 2 NHCH 2 —，HOOC—，CH 3 OOC—， 3 HOOC—CH 2 SO 2 NH—，CF 3 —CH 2 SO 2 NH—， 4 R 8 —NHSO 2 —，R 8 —NHSO 2 —CH 2 —，HOOC—CH 2 —O—，HSO 3 N═CH—，或R 9 —SO 2 NHCO—； R 4 为H，OH，O-烷基或O—CH 2 OCH 3 ； R 5 为H，卤原子，—CH 2 COOH或OH； R 6 和R 7 为氢，叔丁基或吡咯烷基； R 8 为氢或较低烷基； R 9 为烷基或噻吩基； R 10 为较低烷基） 或药用可接受盐。
• Carboxylic acid derivatives and drugs containing the same as the active ingredient
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：US06506757B1

  公开（公告）日：2003-01-14

  A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

  一种含有化学式(I)的羧酸衍生物的过氧化物酶增殖激活受体调节剂（其中所有符号均如规范中定义），其非毒性酸或其水合物作为活性成分。由于具有调节PPAR的作用，化学式(I)的化合物可用作降糖剂、降脂剂、与代谢紊乱（糖尿病、肥胖、X综合征、高胆固醇血症、高脂蛋白血症等）相关的疾病的预防和/或治疗、高脂血症、动脉粥样硬化、高血压、循环系统疾病、暴饮暴食、冠心病等，以及提高HDL胆固醇的药物、降低LDL胆固醇和/或VLDL胆固醇的药物，以及缓解疾病或X综合征风险因素的药物。
• Thiazolidinediones and drugs containing them
  申请人：Boehringer Mannheim GmbH

  公开号：US05599826A1

  公开（公告）日：1997-02-04

  Compounds of formula I ##STR1## in which A denotes a carbocyclic ring with 5 or 6 carbon atoms or a heterocyclic ring with a maximum of 4 heteroatoms in which the heteroatoms can be the same or different and denote oxygen, nitrogen or sulphur and the heterocycles can if desired carry an oxygen atom on one or several nitrogen atoms, B denotes --CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N--, O or S, W denotes CH.sub.2, O, CH(OH), CO or --CH.dbd.CH--, X denotes S, O or NR.sup.2 in which the residue R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl, Y is CH or N, R denotes naphthyl, pyridyl, furyl, thienyl or phenyl which if desired is mono- or disubstituted with C.sub.1 -C.sub.3 alkyl, CF.sub.3, C.sub.1 -C.sub.3 alkoxy, F, Cl or bromine, R.sup.1 denotes hydrogen or C.sub.1 -C.sub.6 alkyl and n equals 1-3 as well as their tautomers, enantiomers, diastereomers and physiologically tolerated salts, processes for their production as well as pharmaceutical agents that contain these compounds for the treatment of diabetes.

  化学式I的化合物##STR1##中，其中A表示具有5或6个碳原子的碳环或最多含有4个杂原子的杂环，其中杂原子可以相同也可以不同，并表示氧、氮或硫，如果需要，杂环可以在一个或多个氮原子上携带一个氧原子，B表示--CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N--, O或S，W表示CH.sub.2、O、CH(OH)、CO或--CH.dbd.CH--，X表示S、O或NR.sup.2，其中残基R.sup.2是氢或C.sub.1 -C.sub.6烷基，Y是CH或N，R表示萘基、吡啶基、呋喃基、噻吩基或苯基，如果需要，可以是单取代或双取代的C.sub.1 -C.sub.3烷基、CF.sub.3、C.sub.1 -C.sub.3烷氧基、F、Cl或溴，R.sup.1表示氢或C.sub.1 -C.sub.6烷基，n等于1-3，以及它们的互变异构体、对映异构体、非对映异构体和生理耐受的盐，它们的制备方法以及包含这些化合物用于治疗糖尿病的药物。